You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Pipeline Information

Development Programs – Solid Tumor

Drug

Indication

Phase 1

Phase 2

Phase 3


BGB-3245 (BRAF inhibitor)

Advanced solid tumors with B-RAF mutations

Lifirafenib (RAF inhibitor) + PD-0325901 (MEK inhibitor)

Advanced solid tumors

Pamiparib (PARP 1/2 inhibitor)

2L/3L maintenance platinum-sensitive OC

1L maintenance platinum-sensitive GC

≥2L CTC HRD+ mCRPC

BRCA+ and HER2– BC

Advanced OC and TNBC

Pamiparib + Radiotherapy and/or Temozolomide

1L or R/R GBM

Pamiparib + Temozolomide

Advanced solid tumors

Tislelizumab (anti-PD-1)

2L advanced ESCC

1L HCC

2L/3L NSCLC

Advanced UBC

Previously treated unresectable HCC

Previously treated advanced MSI-high or dMMR solid tumors

Advanced solid tumors

Advanced solid tumors

Tislelizumab + BGB-A333 (anti-PD-L1)

Advanced solid tumors

Tislelizumab + BGB-A425 (anti-TIM-3)

Advanced solid tumors

Tislelizumab + BGB-A445 (anti-OX40)

Advanced solid tumors

Tislelizumab + BGB-A1217 (anti-TIGIT)

Advanced solid tumors

Tislelizumab + BGB-10188 (PI3Kδ inhibitor)

Advanced solid tumors

Tislelizumab + Chemoradiotherapy

Localized ESCC

Tislelizumab + Chemotherapy

1L advanced ESCC

1L GC/GEJC

Resectable stage II or IIIA NSCLC

1L advanced nasopharyngeal cancer

1L squamous NSCLC

1L non-squamous NSCLC

1L advanced UBC

1L ES-SCLC

1L GC/GEJC/ESCC

1L SCLC and NSCLC

Tislelizumab + DKN-01 (anti-DKK1) + Chemotherapy

1L/2L GC/GEJC

Tislelizumab + Lenvatinib

1L HCC

Tislelizumab + Pamiparib

Advanced solid tumors

Tislelizumab + Sitravatinib (multikinase inhibitor)

Advanced GC/GEJC/HCC

Advanced solid tumors

Zanidatamab (anti-HER2 bispecific antibody)

2L+ HER2+ BTC

Zanidatamab + Chemotherapy +/- Tislelizumab

1L HER2+ BC and 1L HER2+ GC/GEJC

Australia
Australia, China
China
China, S. Korea
China, Taiwan, Thailand
S. Korea, Taiwan
US, Australia
United States
Worldwide

BC, breast cancer BRCA+, breast cancer susceptibility gene-positive; dMMR, deficient mismatch repair; ESCC, esophageal squamous cell carcinoma; ES-SCLC; extensive-stage small cell lung cancer; GC, gastric cancer; GEJC, gastroesophageal junction carcinoma; HCC, hepatocelluar carcinoma; HER2-, human epidermal growth factor receptor-2–negative; HER2+, human epidermal growth factor receptor-2–positive; MSI, microsatellite instability; NSCLC, non-small cell lung cancer; OC, ovarian cancer; R/R, recurrent/refractory; SCLC, small lung cell cancer; TNBC, triple-negative breast cancer; UBC, urothelial bladder cancer.

Development Programs – Hematology

Drug

Indication

Phase 1

Phase 2

Phase 3


Tislelizumab (anti-PD-1)

R/R mature T- and NK-cell neoplasms

R/R cHL

R/R cHL

BGB-10188 (PI3Kδ inhibitor) +/- Zanubrutinib (BTK inhibitor)

B-cell lymphoid malignancies

BGB-11417 (Bcl-2 inhibitor) monotherapy

Mature B-cell malignancies

ME-401 (PI3Kδ inhibitor) +/- Zanubrutinib or Rituximab*

CLL/SLL, and B-cell NHL

Zanubrutinib

R/R CLL/SLL

1L and R/R WM

R/R CLL/SLL

R/R MCL

R/R non-GCB type DLBCL

R/R WM

R/R MZL

B-cell lymphoid malignancies

Previously treated B-cell lymphoid malignancies

B-cell lymphoid malignancies

B-cell lymphoid malignancies

Zanubrutinib + Obinutuzumab

R/R FL

B-cell lymphoid malignancies

Zanubrutinib + Rituximab

1L MCL

R/R DLBCL (non-GCB) and R/R indolent lymphoma (FL, MZL)

Zanubrutinib + Tislelizumab

B-cell lymphoid malignancies

Zanubrutinib +/- Venetoclax

1L CLL/SLL

Australia
Australia, China
China
Japan
United States
United States, Switzerland
Worldwide

* In collaboration with MEI Pharma
This combination is being studied in the third cohort of NCT03336333

BC, breast cancer; B-cell NHL, B-cell non-Hodgkins lymphoma; cHL, classical Hodgkin lymphoma; CLL, chronic lymphotic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; GCB, germinal center B cell-like; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; NK, natural killer; R/R, recurrent/refractory; SLL, small lymphocytic lymphoma; WM, Waldenstrӧm macroglobulinemia.

Videos

Anti-PD-1 Mechanism of Action

BTKI Mechanism of Action